Actively Recruiting
A Study to Evaluate CM336 in Adults With Autoimmune Bullous Disease
Led by Shandong First Medical University · Updated on 2026-04-06
30
Participants Needed
1
Research Sites
140 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
to Evaluate the Efficacy and Safety of CM336 (BCMA/CD3 Bispecific Antibody) in Adults with Moderate to Severe Autoimmune Bullous Disease
CONDITIONS
Official Title
A Study to Evaluate CM336 in Adults With Autoimmune Bullous Disease
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Confirmed diagnosis of autoimmune bullous disease
- Age 18 years or older
- Voluntarily signed informed consent form, understanding study details and willing to comply with trial requirements
You will not qualify if you...
- History of clinically significant diseases posing safety risks during participation
- Prior treatment with anti-B-cell maturation antigen (BCMA) therapy
- History of allergic reactions to humanized monoclonal antibodies or known allergy to any component of CM336
- Any other condition deemed unsuitable for study participation by the investigator
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Dermatology Hospital Affiliated to Shandong First Medical University
Jinan, China
Actively Recruiting
Research Team
F
Furen Zhang
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here